Increasing Biosimilar Use Reflects Changing Practice in Pediatric IBD Care

June 25, 2025

Pediatric infliximab biosimilar use has risen significantly, reflecting evolving treatment patterns in inflammatory bowel disease (IBD) among children and young adults.

Omalizumab Biosimilar Matches Reference Product in Chronic Spontaneous Urticaria

June 24, 2025

BioRationality: Questioning Experts and Journals Reporting on Biosimilar Bill to Remove Interchangeability

June 23, 2025

Long-Term Durability and Cost-Effectiveness of Adalimumab Biosimilars in Pediatric IBD

June 22, 2025

The Top 5 Biosimilars Articles for the Week of June 16

June 20, 2025

How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment

March 9th 2025

By Skylar Jeremias

Podcast

Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?

FDA Approves First Omalizumab Biosimilar

March 7th 2025

By Skylar Jeremias

Article

Celltrion's Omlyclo (omalizumab-igec) is the first omalizumab biosimilar to be approved for US patients, and it was approved with interchangeability, making it easier for patients to switch to the Xolair competitor.

The Top 5 Biosimilar Articles for the Week of March 3

March 7th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of March 3, 2025.

From Amjevita to Zarxio: A Decade of US Biosimilar Approvals

March 6th 2025

By Skylar Jeremias

Article

Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.

Pharmacists Play a Crucial Role in Adalimumab Biosimilars for Patient Care

March 5th 2025

By Kennedy Ferruggia

Article

Adalimumab biosimilars differ from adalimumab in approved indications, concentration and dosage, and formulation.

FDA Approves Third Pair of Denosumab Biosimilars

March 4th 2025

By Skylar Jeremias

Article

The approvals for Celltrion's denosumab-bmwo (Stoboclo and Osenvelt) mark the third FDA green light for a biosimilar to treat osteoporosis and bone metastases.

No IBD Activity Changes Following Switch From Biosimilar to Originator Infliximab

March 3rd 2025

By Deana Ferreri, PhD

Article

A prospective cohort study found that switching back from the biosimilar SB2 to the reference infliximab did not affect clinical disease activity or safety in inflammatory bowel disease (IBD).

Biosimilars Regulatory Roundup: February 2025

March 1st 2025

By Rose McNulty

Article

February brought policy updates and several biosimilar approvals, including the first FDA approval for an insulin aspart biosimilar.

The Top 5 Biosimilar Articles for the Week of February 24

February 28th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of February 24, 2025.

Bevacizumab Biosimilars Show Similar Efficacy, Safety in NSCLC

February 27th 2025

By Cameron Santoro

Article

Patients with non-small cell lung cancer (NSCLC) taking bevacizumab biosimilars demonstrated equivalent therapeutic efficacy and similar safety profiles to those taking the originator product, Avastin.